Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients

J Nutr Biochem. 2022 Aug:106:109021. doi: 10.1016/j.jnutbio.2022.109021. Epub 2022 Apr 25.

Abstract

Weight loss is recommended for obese patients with cardiovascular risk; however, it remains questionable how hyperglycemia affects this process. To address this problem, we aimed to determine the association between weight loss, lipid profile, and body mass parameters in obese normoglycemic and hyperglycemic patients. Obese (body mass index30 kg/m2) normoglycemic and hyperglycemic volunteers were placed on a weight reduction program that included a balanced, low-calorie diet and moderate exercise for 6 months. Participants were assessed for serum glucose, β-cell functions, insulin resistance, lipid metabolism, lipoprotein profile, and body mass parameters. This weight reduction program fully normalized serum glucose levels only in a subpopulation of patients. These individuals also exhibited a significant reduction in body weight, and significant improvement in serum lipid profile and insulin resistance. In contrast, the patients that remained hyperglycemic were characterized by persistent insulin resistance, increased levels of atherogenic fractions of LDL and HDL lipoproteins, and elevated values of a modified Atherogenic Index of Plasma. Correlation analysis indicated a strong positive association between the modified Atherogenic Index of Plasma with atherogenic lipid profile, insulin resistance, and body mass parameters, indicating its usefulness in clinical studies in obese patients. Overall, our data indicate that successful treatment of hyperglycemia facilitates weight loss and improves the composition of blood lipids, while persisting hyperglycemia negatively affects the weight loss process and maintains an atherogenic lipid profile. Because hyperglycemia predisposes to cardiovascular disorders, its correction should be the primary goal during weight reduction therapy.

Keywords: Anthropometric parameters; Atherogenic Index of Plasma (AIP); HOMA-IR, lipoproteins; glycemia; weight loss.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis*
  • Body Mass Index
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Glucose
  • Heart Disease Risk Factors
  • Humans
  • Hyperglycemia* / complications
  • Insulin Resistance* / physiology
  • Lipids
  • Obesity / metabolism
  • Risk Factors
  • Weight Loss

Substances

  • Lipids
  • Glucose